Vertex Pharmaceuticals is getting deeper into in vivo gene editing. Months after partnering with Mammoth Biosciences, the storied biotech is back with another deal, ponying up $60 million to work with ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Vertex has regained limited rights to two DNA-dependent protein kinase (DNA-PK) inhibitors from Merck KGaA. Merck licensed the drugs and other assets for $230 million upfront two years ago but has now ...

Vertex Pharmaceuticals (NASDAQ: VRTX) and its partner, CRISPR Therapeutics (NASDAQ: CRSP), have achieved significant progress with their drug targeting rare blood diseases beta thalassemia and sickle ...

Editas Medicine, Inc. EDIT announced entering into a licensing agreement with Vertex Pharmaceuticals VRTX for the development of the latter’s new sickle cell disease (SCD) gene therapy, Casgevy. Per ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals will work together with Orna ...